Addressing the threat of drug-resistant tuberculosis [[electronic resource] ] : a realistic assessment of the challenge : workshop summary / / Robert Giffin and Sally Robinson, rapporteurs; Institute of Medicine of the National Academies |
Pubbl/distr/stampa | Washington, D.C., : National Academies Press, 2009 |
Descrizione fisica | 1 online resource (253 p.) |
Disciplina | 616.9 |
Altri autori (Persone) |
GiffinRobert B
RobinsonSally |
Soggetto topico |
Multidrug-resistant tuberculosis
Tuberculosis Drug resistance Antitubercular agents |
Soggetto genere / forma | Electronic books. |
ISBN |
1-282-45484-6
9786612454844 0-309-13045-X |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
""Reviewers""; ""Contents""; ""Tables, Figures, and Boxes""; ""Acronyms""; ""Summary""; ""1 Introduction""; ""2 The Global Spread of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis""; ""3 MDR TB Transmission, HIV Coinfection, and Transmission Control""; ""4 Diagnosis""; ""5 Infrastructure and Health Care Delivery Systems""; ""6 Global Systems for the Purchase and Delivery of TB Drugs""; ""7 Research on the Global Control of TB: Understanding the Role of Drugs, Vaccines, and Funding""; ""8 Strategies for Confronting the Global MDR and XDR TB Crisis""; ""References""
""Appendix A: Agenda""""Appendix B: Participant Biographies""; ""Appendix C: Partners In Health White Paper�Stemming the Tide of Multidrug-Resistant Tuberculosis: Major Barriers to Addressing the Growing Epidemic"" |
Record Nr. | UNINA-9910456590803321 |
Washington, D.C., : National Academies Press, 2009 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Addressing the threat of drug-resistant tuberculosis [[electronic resource] ] : a realistic assessment of the challenge : workshop summary / / Robert Giffin and Sally Robinson, rapporteurs; Institute of Medicine of the National Academies |
Pubbl/distr/stampa | Washington, D.C., : National Academies Press, 2009 |
Descrizione fisica | 1 online resource (253 p.) |
Disciplina | 616.9 |
Altri autori (Persone) |
GiffinRobert B
RobinsonSally |
Soggetto topico |
Multidrug-resistant tuberculosis
Tuberculosis Drug resistance Antitubercular agents |
ISBN |
0-309-14874-X
1-282-45484-6 9786612454844 0-309-13045-X |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto | Reviewers -- Contents -- Tables, Figures, and Boxes -- Acronyms -- Summary -- Chapter 1. Introduction -- Chapter 2. The Global Spread of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis -- Chapter 3. MDR TB Transmission, HIV Coinfection, and Transmission Control -- Chapter 4. Diagnosis -- Chapter 6. Infrastructure and Health Care Delivery Systems -- 6 Global Systems for the Purchase and Delivery of TB Drugs -- Chapter 7. Research on the Global Control of TB: Understanding the Role of Drugs, Vaccines, and Funding -- Chapter 8. Strategies for Confronting the Global MDR and XDR TB Crisis -- References. -- Appendix A: Agenda -- Appendix B: Participant Biographies -- Appendix C: Partners In Health White Paper' stemming the Tide of Multidrug-Resistant Tuberculosis: Major Barriers to Addressing the Growing Epidemic -- |
Record Nr. | UNINA-9910781187903321 |
Washington, D.C., : National Academies Press, 2009 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Addressing the threat of drug-resistant tuberculosis : a realistic assessment of the challenge : workshop summary / / Robert Giffin and Sally Robinson, rapporteurs; Institute of Medicine of the National Academies |
Edizione | [1st ed.] |
Pubbl/distr/stampa | Washington, D.C., : National Academies Press, 2009 |
Descrizione fisica | 1 online resource (253 p.) |
Disciplina | 616.9 |
Altri autori (Persone) |
GiffinRobert B
RobinsonSally |
Soggetto topico |
Multidrug-resistant tuberculosis
Tuberculosis Drug resistance Antitubercular agents |
ISBN |
0-309-14874-X
1-282-45484-6 9786612454844 0-309-13045-X |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto | Reviewers -- Contents -- Tables, Figures, and Boxes -- Acronyms -- Summary -- Chapter 1. Introduction -- Chapter 2. The Global Spread of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis -- Chapter 3. MDR TB Transmission, HIV Coinfection, and Transmission Control -- Chapter 4. Diagnosis -- Chapter 6. Infrastructure and Health Care Delivery Systems -- 6 Global Systems for the Purchase and Delivery of TB Drugs -- Chapter 7. Research on the Global Control of TB: Understanding the Role of Drugs, Vaccines, and Funding -- Chapter 8. Strategies for Confronting the Global MDR and XDR TB Crisis -- References. -- Appendix A: Agenda -- Appendix B: Participant Biographies -- Appendix C: Partners In Health White Paper' stemming the Tide of Multidrug-Resistant Tuberculosis: Major Barriers to Addressing the Growing Epidemic -- |
Record Nr. | UNINA-9910819902103321 |
Washington, D.C., : National Academies Press, 2009 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Advances in tuberculosis medicinal chemistry / / editors, Michio Kurosu, William Denny |
Pubbl/distr/stampa | London, England : , : Future Science Ltd, , 2016 |
Descrizione fisica | 1 online resource (151 pages) : illustrations (some color) |
Disciplina | 616.995 |
Collana | Future Science |
Soggetto topico |
Tuberculosis
Tuberculosis - Diagnosis |
Soggetto genere / forma | Electronic books. |
ISBN |
1-910419-15-X
1-910419-14-1 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Record Nr. | UNINA-9910467808603321 |
London, England : , : Future Science Ltd, , 2016 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Advances in tuberculosis medicinal chemistry / / editors, Michio Kurosu, William Denny |
Pubbl/distr/stampa | London, England : , : Future Science Ltd, , 2016 |
Descrizione fisica | 1 online resource (151 pages) : illustrations (some color) |
Disciplina | 616.995 |
Collana | Future Science |
Soggetto topico |
Tuberculosis
Tuberculosis - Diagnosis |
ISBN |
1-910419-15-X
1-910419-14-1 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Record Nr. | UNINA-9910794873103321 |
London, England : , : Future Science Ltd, , 2016 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Advances in tuberculosis medicinal chemistry / / editors, Michio Kurosu, William Denny |
Pubbl/distr/stampa | London, England : , : Future Science Ltd, , 2016 |
Descrizione fisica | 1 online resource (151 pages) : illustrations (some color) |
Disciplina | 616.995 |
Collana | Future Science |
Soggetto topico |
Tuberculosis
Tuberculosis - Diagnosis |
ISBN |
1-910419-15-X
1-910419-14-1 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Record Nr. | UNINA-9910812995703321 |
London, England : , : Future Science Ltd, , 2016 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
AIDS and tuberculosis [[electronic resource] ] : a deadly liaison / / ed. by Stefan H. E. Kaufmann and Bruce D. Walker |
Pubbl/distr/stampa | Weinheim, : Wiley-VCH, 2009 |
Descrizione fisica | 1 online resource (322 p.) |
Disciplina |
616.9792
616.9792 20 |
Altri autori (Persone) | KaufmannS. H. E (Stefan H. E.) |
Collana | Infection biology handbook series |
Soggetto topico |
AIDS (Disease) - Complications
Tuberculosis |
ISBN |
1-282-30250-7
9786612302503 3-527-62790-1 3-527-62791-X |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
AIDS and Tuberculosis: A Deadly Liaison; Contents; Preface; List of Contributors; Part One: Immunology and Vaccination Strategies for AIDS and TB; 1 HIV Immunology and Prospects for Vaccines; 1.1 Introduction; 1.2 Challenges for HIV Vaccine Design; 1.3 What Immune Responses will be Required for an Effective AIDS Vaccine?; 1.3.1 Cytotoxic T Lymphocytes; 1.3.2 Neutralizing Antibodies; 1.3.3 CD4+ T Helper Cells; 1.3.4 Natural Killer Cells; 1.4 Models of Successful Vaccination?; 1.5 Human Trials of AIDS Vaccines; 1.5.1 Antibody-Based Vaccination; 1.5.1.1 VaxGen Trial of AIDSVax
1.5.2 T Cell-Based Vaccination1.5.2.1 The STEP Study; 1.6 Recent Advances in Animal Models: Reasons for Optimism; 1.6.1 Success against Heterologous Challenge; 1.6.2 Heterologous rAd26 Prime/rAd5 Boost Vaccine Regimen; 1.6.3 Induction of Effector Memory T-Cell Responses at Viral Entry Sites; 1.7 The Current Vaccine Pipeline; 1.7.1 DNA; 1.7.2 Adenovirus; 1.7.3 Peptides; 1.7.4 Bacillus Calmette-Guérin; 1.7.5 Listeria and Other Bacterial Vectors; 1.7.5.1 Listeria monocytogenes; 1.7.5.2 Salmonella enterica; 1.7.5.3 Shigella; 1.7.6 Canarypox; 1.7.7 Adeno-Associated Virus 1.8 Conclusions and Future DirectionsReferences; 2 Immune Response to Tuberculosis as a Basis for Rational Vaccination Strategies; 2.1 Introduction; 2.2 Clinical Aspects of TB; 2.3 Immune Response to TB: Innate Immunity; 2.4 Adaptive Immunity; 2.4.1 T-Cell Subsets; 2.4.2 T-Cell Activation; 2.5 Cytokines as Mediators of Immune Function; 2.5.1 IL-12 Family of Cytokines; 2.5.2 Tumor Necrosis Factor; 2.6 Vaccines against TB; 2.6.1 From the Past to the Present; 2.6.2 The Future; 2.6.2.1 Goals of Vaccination; 2.6.2.2 Vaccination Strategies; 2.6.2.3 Targets for Vaccination; 2.7 Biomarkers 2.7.1 Immunologic2.7.2 Transcriptomics; 2.7.3 Proteomics; 2.7.4 Metabolomics; 2.8 Concluding Remarks; References; 3 BCG Vaccination in the HIV+Newborn; 3.1 Bacillus Calmette-Gu erin (BCG) and its Efficacy in Healthy Infants; 3.2 Adverse Events Caused by BCG in Healthy Infants; 3.3 Specific Immunity Induced by BCG in Healthy Infants; 3.4 Efficacy of BCG to Prevent TB in HIV-Infected Infants; 3.5 Adverse Effects Caused by BCG in HIV-Infected Infants not Receiving Antiretroviral Therapy; 3.6 BCG Immune Reconstitution Inflammatory Syndrome (BCG-IRIS) 3.7 Management of BCG Disease in HIV-Infected Infants3.8 Specific Immunity Induced by BCG in HIV-Infected Infants; 3.9 Weighing up the Evidence: Should BCG be given to HIV-Infected or HIV-Exposed Infants?; 3.10 How Can We Protect HIV-Infected Infants Against TB, if BCG is Not Given?; 3.11 BCG Vaccination of HIV-Exposed, Uninfected Infants; 3.12 Conclusions; References; Part Two: Drugs; 4 HIV/AIDS Drugs; 4.1 Introduction; 4.2 Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs); 4.3 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs); 4.4 HIV Protease Inhibitors 4.5 Newer Classes: Entry Inhibitors and Integrase Inhibitors |
Record Nr. | UNINA-9910139928003321 |
Weinheim, : Wiley-VCH, 2009 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
AIDS and tuberculosis [[electronic resource] ] : a deadly liaison / / ed. by Stefan H. E. Kaufmann and Bruce D. Walker |
Pubbl/distr/stampa | Weinheim, : Wiley-VCH, 2009 |
Descrizione fisica | 1 online resource (322 p.) |
Disciplina |
616.9792
616.9792 20 |
Altri autori (Persone) | KaufmannS. H. E (Stefan H. E.) |
Collana | Infection biology handbook series |
Soggetto topico |
AIDS (Disease) - Complications
Tuberculosis |
ISBN |
1-282-30250-7
9786612302503 3-527-62790-1 3-527-62791-X |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
AIDS and Tuberculosis: A Deadly Liaison; Contents; Preface; List of Contributors; Part One: Immunology and Vaccination Strategies for AIDS and TB; 1 HIV Immunology and Prospects for Vaccines; 1.1 Introduction; 1.2 Challenges for HIV Vaccine Design; 1.3 What Immune Responses will be Required for an Effective AIDS Vaccine?; 1.3.1 Cytotoxic T Lymphocytes; 1.3.2 Neutralizing Antibodies; 1.3.3 CD4+ T Helper Cells; 1.3.4 Natural Killer Cells; 1.4 Models of Successful Vaccination?; 1.5 Human Trials of AIDS Vaccines; 1.5.1 Antibody-Based Vaccination; 1.5.1.1 VaxGen Trial of AIDSVax
1.5.2 T Cell-Based Vaccination1.5.2.1 The STEP Study; 1.6 Recent Advances in Animal Models: Reasons for Optimism; 1.6.1 Success against Heterologous Challenge; 1.6.2 Heterologous rAd26 Prime/rAd5 Boost Vaccine Regimen; 1.6.3 Induction of Effector Memory T-Cell Responses at Viral Entry Sites; 1.7 The Current Vaccine Pipeline; 1.7.1 DNA; 1.7.2 Adenovirus; 1.7.3 Peptides; 1.7.4 Bacillus Calmette-Guérin; 1.7.5 Listeria and Other Bacterial Vectors; 1.7.5.1 Listeria monocytogenes; 1.7.5.2 Salmonella enterica; 1.7.5.3 Shigella; 1.7.6 Canarypox; 1.7.7 Adeno-Associated Virus 1.8 Conclusions and Future DirectionsReferences; 2 Immune Response to Tuberculosis as a Basis for Rational Vaccination Strategies; 2.1 Introduction; 2.2 Clinical Aspects of TB; 2.3 Immune Response to TB: Innate Immunity; 2.4 Adaptive Immunity; 2.4.1 T-Cell Subsets; 2.4.2 T-Cell Activation; 2.5 Cytokines as Mediators of Immune Function; 2.5.1 IL-12 Family of Cytokines; 2.5.2 Tumor Necrosis Factor; 2.6 Vaccines against TB; 2.6.1 From the Past to the Present; 2.6.2 The Future; 2.6.2.1 Goals of Vaccination; 2.6.2.2 Vaccination Strategies; 2.6.2.3 Targets for Vaccination; 2.7 Biomarkers 2.7.1 Immunologic2.7.2 Transcriptomics; 2.7.3 Proteomics; 2.7.4 Metabolomics; 2.8 Concluding Remarks; References; 3 BCG Vaccination in the HIV+Newborn; 3.1 Bacillus Calmette-Gu erin (BCG) and its Efficacy in Healthy Infants; 3.2 Adverse Events Caused by BCG in Healthy Infants; 3.3 Specific Immunity Induced by BCG in Healthy Infants; 3.4 Efficacy of BCG to Prevent TB in HIV-Infected Infants; 3.5 Adverse Effects Caused by BCG in HIV-Infected Infants not Receiving Antiretroviral Therapy; 3.6 BCG Immune Reconstitution Inflammatory Syndrome (BCG-IRIS) 3.7 Management of BCG Disease in HIV-Infected Infants3.8 Specific Immunity Induced by BCG in HIV-Infected Infants; 3.9 Weighing up the Evidence: Should BCG be given to HIV-Infected or HIV-Exposed Infants?; 3.10 How Can We Protect HIV-Infected Infants Against TB, if BCG is Not Given?; 3.11 BCG Vaccination of HIV-Exposed, Uninfected Infants; 3.12 Conclusions; References; Part Two: Drugs; 4 HIV/AIDS Drugs; 4.1 Introduction; 4.2 Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs); 4.3 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs); 4.4 HIV Protease Inhibitors 4.5 Newer Classes: Entry Inhibitors and Integrase Inhibitors |
Record Nr. | UNINA-9910831001303321 |
Weinheim, : Wiley-VCH, 2009 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
AIDS and tuberculosis : a deadly liaison / / ed. by Stefan H. E. Kaufmann and Bruce D. Walker |
Pubbl/distr/stampa | Weinheim, : Wiley-VCH, 2009 |
Descrizione fisica | 1 online resource (322 p.) |
Disciplina |
616.9792
616.9792 20 |
Altri autori (Persone) | KaufmannS. H. E (Stefan H. E.) |
Collana | Infection biology handbook series |
Soggetto topico |
AIDS (Disease) - Complications
Tuberculosis |
ISBN |
1-282-30250-7
9786612302503 3-527-62790-1 3-527-62791-X |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
AIDS and Tuberculosis: A Deadly Liaison; Contents; Preface; List of Contributors; Part One: Immunology and Vaccination Strategies for AIDS and TB; 1 HIV Immunology and Prospects for Vaccines; 1.1 Introduction; 1.2 Challenges for HIV Vaccine Design; 1.3 What Immune Responses will be Required for an Effective AIDS Vaccine?; 1.3.1 Cytotoxic T Lymphocytes; 1.3.2 Neutralizing Antibodies; 1.3.3 CD4+ T Helper Cells; 1.3.4 Natural Killer Cells; 1.4 Models of Successful Vaccination?; 1.5 Human Trials of AIDS Vaccines; 1.5.1 Antibody-Based Vaccination; 1.5.1.1 VaxGen Trial of AIDSVax
1.5.2 T Cell-Based Vaccination1.5.2.1 The STEP Study; 1.6 Recent Advances in Animal Models: Reasons for Optimism; 1.6.1 Success against Heterologous Challenge; 1.6.2 Heterologous rAd26 Prime/rAd5 Boost Vaccine Regimen; 1.6.3 Induction of Effector Memory T-Cell Responses at Viral Entry Sites; 1.7 The Current Vaccine Pipeline; 1.7.1 DNA; 1.7.2 Adenovirus; 1.7.3 Peptides; 1.7.4 Bacillus Calmette-Guérin; 1.7.5 Listeria and Other Bacterial Vectors; 1.7.5.1 Listeria monocytogenes; 1.7.5.2 Salmonella enterica; 1.7.5.3 Shigella; 1.7.6 Canarypox; 1.7.7 Adeno-Associated Virus 1.8 Conclusions and Future DirectionsReferences; 2 Immune Response to Tuberculosis as a Basis for Rational Vaccination Strategies; 2.1 Introduction; 2.2 Clinical Aspects of TB; 2.3 Immune Response to TB: Innate Immunity; 2.4 Adaptive Immunity; 2.4.1 T-Cell Subsets; 2.4.2 T-Cell Activation; 2.5 Cytokines as Mediators of Immune Function; 2.5.1 IL-12 Family of Cytokines; 2.5.2 Tumor Necrosis Factor; 2.6 Vaccines against TB; 2.6.1 From the Past to the Present; 2.6.2 The Future; 2.6.2.1 Goals of Vaccination; 2.6.2.2 Vaccination Strategies; 2.6.2.3 Targets for Vaccination; 2.7 Biomarkers 2.7.1 Immunologic2.7.2 Transcriptomics; 2.7.3 Proteomics; 2.7.4 Metabolomics; 2.8 Concluding Remarks; References; 3 BCG Vaccination in the HIV+Newborn; 3.1 Bacillus Calmette-Gu erin (BCG) and its Efficacy in Healthy Infants; 3.2 Adverse Events Caused by BCG in Healthy Infants; 3.3 Specific Immunity Induced by BCG in Healthy Infants; 3.4 Efficacy of BCG to Prevent TB in HIV-Infected Infants; 3.5 Adverse Effects Caused by BCG in HIV-Infected Infants not Receiving Antiretroviral Therapy; 3.6 BCG Immune Reconstitution Inflammatory Syndrome (BCG-IRIS) 3.7 Management of BCG Disease in HIV-Infected Infants3.8 Specific Immunity Induced by BCG in HIV-Infected Infants; 3.9 Weighing up the Evidence: Should BCG be given to HIV-Infected or HIV-Exposed Infants?; 3.10 How Can We Protect HIV-Infected Infants Against TB, if BCG is Not Given?; 3.11 BCG Vaccination of HIV-Exposed, Uninfected Infants; 3.12 Conclusions; References; Part Two: Drugs; 4 HIV/AIDS Drugs; 4.1 Introduction; 4.2 Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs); 4.3 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs); 4.4 HIV Protease Inhibitors 4.5 Newer Classes: Entry Inhibitors and Integrase Inhibitors |
Record Nr. | UNINA-9910877543903321 |
Weinheim, : Wiley-VCH, 2009 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Assessing tuberculosis prevalence through population-based surveys [[electronic resource]] |
Pubbl/distr/stampa | Geneva, : World Health Organization, 2007 |
Descrizione fisica | 1 online resource (248 p.) |
Disciplina | 362.196995 |
Soggetto topico |
Tuberculosis
Public health |
Soggetto genere / forma | Electronic books. |
ISBN | 92-9061-466-8 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto | COVER; COPYRIGHT; Acknowledgements; Errata; Contents; Executive Summary; Annexes |
Record Nr. | UNINA-9910459948203321 |
Geneva, : World Health Organization, 2007 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|